Success Story: We Helped a Neurology Researcher Secure EB-1A Approval After RFE
Client’s Testimonial:
"It was great working with you. Appreciate your dedication towards clients.”
On June 29th, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for a Senior Scientist in the Field of Neurology (Approval Notice).
General Field: Neurology
Country of Origin: India
State of Residence at the Time of Filing: Missouri
Approval Notice Date: June 29th, 2026
Processing Time: 11 months, 12 days (Premium Processing Upgrade Requested)
Case Summary:
At the time of filing, the client was continuing research in the United States. Because this was an EB-1A case that later received a Request for Evidence (RFE), our strategy was not simply to list the client’s credentials. Instead, we had to show how the evidence, viewed together, supported extraordinary ability, sustained acclaim, and contributions of major significance in the field.
The client’s scholarly record provided an important foundation for the petition. The client had authored 19 peer-reviewed journal articles, including 6 first- or co-first-authored articles, along with 2 abstracts, one of them first-authored, and 1 first-authored book chapter. These publications showed a consistent research trajectory in neurology and related biomedical topics. More importantly, we framed the publication record as evidence that the client’s work had passed through selective scientific review and had become part of the broader research discussion in neuro-oncology and brain tumor studies.
The citation record also played a key role. The client’s research had been cited 430 times, reflecting substantial reliance by other researchers. We did not present this number as automatically sufficient for EB-1A approval. Rather, we explained how an adjudicator could interpret the citations as independent recognition of the client’s work, especially where other scholars used the client’s findings to advance research on glioma progression, immune modulation, radiation-related cellular stress, and brain tumor mechanisms. This helped demonstrate that the client’s work had influenced the field beyond the client’s own laboratory or immediate collaborations.
The client’s peer-review record further supported the case. With at least 23 completed reviews, the client had been entrusted to evaluate the work of other researchers in the same or related fields. In the EB-1A context, this evidence was significant because it showed that journals and editors viewed the client as qualified to assess scientific quality and validity. We used this point to support the judging criterion and to reinforce the broader argument that the client had earned professional trust within the field.
The petition also emphasized the funding connected to the client’s work. The client’s research had received support from major organizations and agencies connected to cancer research, neurological disorders, pediatric brain tumor research, health science, and related biomedical priorities. We used this evidence carefully, not as a personal award claim, but as context showing that the research areas connected to the client’s work aligned with important scientific and medical priorities.
Recommendation letters were another important part of the presentation. The petition included 4 letters from experts in the field, including independent opinions. These letters helped explain why the client’s contributions mattered, how the client’s findings had been used by others, and why the client’s continued work was valuable to neurology and neuro-oncology research. One recommender noted:
“It is essential that he be allowed to continue his research uninterrupted so that the United States fully benefits from its impact.”
After the RFE, North America Immigration Law Group focused on strengthening the connection between the client’s objective evidence and the EB-1A final merits analysis. We emphasized that the client’s publication record, 430 citations, 23 peer reviews, recognized research focus, funding context, and expert support should be considered together as evidence of sustained acclaim and field-level influence. This approach helped show that the client’s accomplishments were not isolated achievements, but part of a consistent pattern of recognized scientific contribution.
The I-140 EB-1A petition was ultimately approved after RFE. This outcome reflected the importance of presenting a highly technical scientific record in a clear adjudicator-facing structure. By explaining how the client’s work in neurology had been published, cited, reviewed, funded, and externally validated, we demonstrated that the client met the EB-1A standard and had made significant contributions to the field.